Mild cognitive impairment due to Alzheimer's, effective light therapy
Mar 03, 2025
A clinical study has revealed that "light therapy" using light is effective in improving mild cognitive impairment (MCI) caused by Alzheimer's disease.
It is expected that a new field of treatment will be opened beyond existing drug-centered treatments.
Gangnam Bedro Hospital announced that a team of in-house researchers, including neurosurgeon Yoon Kang-joon and Ha Sang-soo, participated in the 「3rd European Society of Neurology and Brain Diseases (ECNN)" and presented the results of a clinical study on the cognitive improvement effect of Alzheimer's MCI patients through transcranial photobiotic modulation (t-PBM).
The ECNN held in Amsterdam on the 17th is one of the large-scale conferences where experts from all over the world gather in the fields of neuroscience and neuropsychiatry. In this year's case, we focused on integrated approaches and solutions to various brain diseases such as Alzheimer's, Parkinson's, and strokes under the theme of 'Brain and Mental Health: Exploring the Future of Neurology and Psychiatry' (Brain and Mental Health:).
In particular, the research team at Gangnam Bedro Hospital drew high interest from the participants of the conference by presenting the only clinical study dealing with phototherapy techniques at this conference. The study was recognized for its achievements by winning the 'Best Original Presentation' given to outstanding oratory presenters.
The research team's announcement of 'photosome modulation technology' is a type of neuromodulation technique and is a new non-invasive nerve control technology that regulates the nervous system and immune system. Near-infrared light strongly penetrates the brain cortex, promoting ATP production in brain cell mitochondria and increased local cerebral blood flow. It has a mechanism that activates and ultimately heals dying cells or tissues. As non-invasive treatment is possible without medication or surgical therapy and the indications are widespread, it is emerging as an innovative treatment for cranial nerve diseases worldwide.
This study was conducted to verify the possibility of improving cognitive function in patients with mild cognitive impairment (MCI) through photobiotic modulation treatment. MCI patients due to Alzheimer's are a group of patients whose cognitive function has decreased but is in the pre-stage of dementia. After selecting a total of 26 male and female Alzheimer's MCI patients between the ages of 55 and 90, t-PBM treatment was conducted six times a week over a total of 12 weeks to investigate near-infrared rays with 808nm wavelengths in the ventral frontal lobe. Treatment was performed through personal medical devices in each patient's home, and the research team measured changes in cognitive function and improvement effects twice at weeks 7 and 13.
Patients who participated in clinical outcomes treatment showed significant improvement in cognitive function compared to placebo group in both Korean-style Montreal Cognitive Assessment (K-MoCA) and Korean-style Simple Mental Health Test (K-MMSE). In particular, there have been no serious clinical side effects, so it has proven to be a relatively safe treatment.
In particular, as it can be used as a home-wearable medical device that can be applied at home, it is expected to be a new turning point for regular treatment of elderly patients who cannot visit hospitals.
Director Ha Sang-soo, who led the study, predicted that it will be possible to commercialize home medical devices for the purpose of delaying or preventing MCI patients from transitioning to Alzheimer's disease in the future, as simple wearing of the device and shining a light on the scalp will have clinical improvement effects.
This study is expected to serve as basic data to explore various possibilities of t-PBM treatments in the future, such as mitigation of MCI progression and prevention of Alzheimer's disease. As the possibility of expansion to the treatment of Parkinson's disease and dementia in general, and other nervous and mental diseases is also open, related follow-up studies are also expected to be more active.
Yoon Kang-joon, CEO of Gangnam Bedro Hospital, said, "It is significant that one in 10 elderly people over the age of 65 are estimated to suffer from dementia ahead of the entry into an ultra-aging society. Therefore, it is significant that it has presented a new treatment approach for the prevention of dementia." Based on our hospital's professional capabilities and know-how in the brain disease sector, we will continue to expand research in the field and lead innovation in treatment in the brain disease sector."
It is expected that a new field of treatment will be opened beyond existing drug-centered treatments.
Gangnam Bedro Hospital announced that a team of in-house researchers, including neurosurgeon Yoon Kang-joon and Ha Sang-soo, participated in the 「3rd European Society of Neurology and Brain Diseases (ECNN)" and presented the results of a clinical study on the cognitive improvement effect of Alzheimer's MCI patients through transcranial photobiotic modulation (t-PBM).
The ECNN held in Amsterdam on the 17th is one of the large-scale conferences where experts from all over the world gather in the fields of neuroscience and neuropsychiatry. In this year's case, we focused on integrated approaches and solutions to various brain diseases such as Alzheimer's, Parkinson's, and strokes under the theme of 'Brain and Mental Health: Exploring the Future of Neurology and Psychiatry' (Brain and Mental Health:).
In particular, the research team at Gangnam Bedro Hospital drew high interest from the participants of the conference by presenting the only clinical study dealing with phototherapy techniques at this conference. The study was recognized for its achievements by winning the 'Best Original Presentation' given to outstanding oratory presenters.
The research team's announcement of 'photosome modulation technology' is a type of neuromodulation technique and is a new non-invasive nerve control technology that regulates the nervous system and immune system. Near-infrared light strongly penetrates the brain cortex, promoting ATP production in brain cell mitochondria and increased local cerebral blood flow. It has a mechanism that activates and ultimately heals dying cells or tissues. As non-invasive treatment is possible without medication or surgical therapy and the indications are widespread, it is emerging as an innovative treatment for cranial nerve diseases worldwide.
This study was conducted to verify the possibility of improving cognitive function in patients with mild cognitive impairment (MCI) through photobiotic modulation treatment. MCI patients due to Alzheimer's are a group of patients whose cognitive function has decreased but is in the pre-stage of dementia. After selecting a total of 26 male and female Alzheimer's MCI patients between the ages of 55 and 90, t-PBM treatment was conducted six times a week over a total of 12 weeks to investigate near-infrared rays with 808nm wavelengths in the ventral frontal lobe. Treatment was performed through personal medical devices in each patient's home, and the research team measured changes in cognitive function and improvement effects twice at weeks 7 and 13.
Patients who participated in clinical outcomes treatment showed significant improvement in cognitive function compared to placebo group in both Korean-style Montreal Cognitive Assessment (K-MoCA) and Korean-style Simple Mental Health Test (K-MMSE). In particular, there have been no serious clinical side effects, so it has proven to be a relatively safe treatment.
In particular, as it can be used as a home-wearable medical device that can be applied at home, it is expected to be a new turning point for regular treatment of elderly patients who cannot visit hospitals.
Director Ha Sang-soo, who led the study, predicted that it will be possible to commercialize home medical devices for the purpose of delaying or preventing MCI patients from transitioning to Alzheimer's disease in the future, as simple wearing of the device and shining a light on the scalp will have clinical improvement effects.
This study is expected to serve as basic data to explore various possibilities of t-PBM treatments in the future, such as mitigation of MCI progression and prevention of Alzheimer's disease. As the possibility of expansion to the treatment of Parkinson's disease and dementia in general, and other nervous and mental diseases is also open, related follow-up studies are also expected to be more active.
Yoon Kang-joon, CEO of Gangnam Bedro Hospital, said, "It is significant that one in 10 elderly people over the age of 65 are estimated to suffer from dementia ahead of the entry into an ultra-aging society. Therefore, it is significant that it has presented a new treatment approach for the prevention of dementia." Based on our hospital's professional capabilities and know-how in the brain disease sector, we will continue to expand research in the field and lead innovation in treatment in the brain disease sector."
|
This article was translated by Naver AI translator.
